Capital Bank & Trust’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-869,698
Closed -$59.9M 79
2021
Q2
$59.9M Buy
869,698
+3,641
+0.4% +$243K 0.69% 51
2021
Q1
$56M Buy
866,057
+53,140
+7% +$3.43M 0.66% 47
2020
Q4
$47.4M Sell
812,917
-63,043
-7% -$3.8M 0.58% 54
2020
Q3
$55.4M Sell
875,960
-28,087
-3% -$1.95M 0.75% 43
2020
Q2
$69.6M Buy
904,047
+34,439
+4% +$2.64M 1.02% 38
2020
Q1
$65M Buy
869,608
+58,569
+7% +$4.05M 1.09% 34
2019
Q4
$52.7M Sell
811,039
-33,584
-4% -$2.19M 0.68% 49
2019
Q3
$53.5M Sell
844,623
-88,537
-9% -$5.79M 0.74% 51
2019
Q2
$63M Sell
933,160
-3,551
-0.4% -$234K 0.78% 55
2019
Q1
$60.8M Sell
936,711
-211,514
-18% -$14.1M 0.77% 53
2018
Q4
$71.8M Sell
1,148,225
-210,795
-16% -$14.7M 1.05% 33
2018
Q3
$105M Sell
1,359,020
-19,099
-1% -$1.44M 1.31% 21
2018
Q2
$97.6M Buy
1,378,119
+163,196
+13% +$11.5M 1.28% 26
2018
Q1
$91.6M Buy
1,214,923
+53,179
+5% +$4.23M 1.24% 25
2017
Q4
$83.2M Sell
1,161,744
-35,984
-3% -$2.73M 1.14% 29
2017
Q3
$97M Buy
1,197,728
+643,218
+116% +$49.2M 1.24% 23
2017
Q2
$39.2M Buy
+554,510
New +$36.9M 0.51% 68

Other funds holding GILD

Capital Bank & Trust's GILD Position: Q3 2021 in Review

Capital Bank & Trust sold out of Gilead Sciences (GILD) in Q3 2021, closing a stake of 869,698 shares — an estimated $59.9M sold.

Capital Bank & Trust first reported a position in GILD in Q2 2017 and held it in 17 quarters. The position peaked at $105M in Q3 2018. 1,563 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

  • Capital Bank & Trust reported no remaining Gilead Sciences position as of Q3 2021 after selling out during the quarter.
  • Capital Bank & Trust sold 869,698 Gilead Sciences shares in Q3 2021, an estimated $59.9M.
  • Capital Bank & Trust first reported a position in Gilead Sciences in Q2 2017 and held it in 17 quarters.
  • Capital Bank & Trust's Gilead Sciences position peaked at $105M in Q3 2018.
  • 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Capital Bank & Trust's 13F filing for Q3 2021, filed 15 Nov 2021.